Forearm vascular responses to arginine vasopressin (AVP) infused into a brachial artery in a wide range of infusion rates (0.05-2.0 ng/kg per min) were examined in 20 young healthy volunteers. Intraarterial AVP at lower doses (0.05 and 0.1 ng/kg per min) caused forearm vasoconstriction, whereas AVP at a dose of 0.2 ng/kg per min or higher caused forearm vasodilatation. The maximal forearm vasoconstriction was induced at the venous plasma AVP level of 76.3±8.8 pg/ml. Forearm vasodilatation was associated with the venous plasma AVP level of 369±43 pg/ml or higher. Forearm vasodilatation was the result of the direct effect of AVP since forearm blood flow and vascular resistance in the contralateral arm did not change. We attempted to explore the mechanisms involved in AVP-induced direct vasodilatation. The treatment with indomethacin, 75 mg/d for 3 d, did not alter AVP-induced forearm vasodilatation. In contrast, intraarterial infusion of isoosmolar CaC12 totally prevented AVP-induced forearm vasodilatation. Intraarterial CaC12 also markedly attenuated forearm vasodilatation induced by intraarterial sodium nitroprusside, but did not alter forearm vasodilatation induced by intraarterial isoproterenol. These results indicate that the direct vascular effects of intraarterial AVP on the forearm vessels are biphasic, causing vasoconstriction at lower doses and vasodilatation at higher doses. The direct vasodilatation induced by intraarterial AVP at higher doses is not mediated by prostaglandins but may involve cGMP-related mechanisms.
Introduction
Arginine vasopressin (AVP)' is a potent vasoconstrictor agent in vitro (1) . However, AVP does not produce the expected rise in blood pressure or vascular resistance when given intravenously to intact animals (2, 3) or humans (4) . Other studies in humans have shown that intravenous AVP at a high dose causes a small transient increase in blood pressure or total peripheral vascular resistance, which returns to the control value despite continued infusion (5, 6) . Furthermore, it has been shown that intravenous AVP at a high dose may even produce forearm vasodilatation in humans (4, 7, 8) .
To explain the difference in the vasoconstrictor effect of AVP between in vivo and in vitro studies, it has been suggested that AVP facilitates baroreflex mechanisms, such that the direct vasoconstrictor effect of AVP is countered by a reflex reduction in heart rate, cardiac output, and peripheral vascular resistance (3, 5, 7, 9-1 1) . However, recent studies in animals have suggested that AVP may induce direct vasodilatation by activating vasodilatory mechanisms in blood vessels. Oliver et al. and Seino et al. have suggested that intraarterial infusion of AVP into the renal artery may cause vasodilatation by augmenting the synthesis of vasodilatory prostaglandins (12, 13) . Others have suggested that AVP may activate endotheliumdependent vasodilatation (14) or produce vasodilatation by stimulating the V2 receptors in blood vessels (15) (16) (17) . These results raise the possibility that activated vasodilatory mechanisms may buffer the direct vasoconstrictor effect of AVP. However, whether these vasodilatory mechanisms play a role in control of circulation by AVP in humans is not known.
A few studies have examined the direct vascular effect of AVP in humans by infusing AVP intraarterially (4, 18) . The results are conflicting with one study reporting vasoconstnction (4) and the other vasodilatation (18) . Thus, the purpose of this study was to assess the direct vascular effect of AVP in humans. We examined forearm vascular responses to AVP infused into a brachial artery in a wide range of infusion rates and correlated vascular responses with the venous plasma AVP levels. In addition, we attempted to explore the mechanisms involved in forearm vasodilatation caused by intraarterial AVP at high doses.
Methods
Subjects. Studies were performed in 20 young healthy volunteers (mean age, 21 .1±0.4 yr; mean body weight, 60.9±1.7 kg, mean±SE). All subjects were male. The study protocol was explained, and informed consent was obtained from each subject.
Measurements offorearm blood flow, arterial pressure, and heart rate. Forearm blood flow was measured using a mercury-in-silastic strain gauge plethysmograph with the venous occlusion technique (19, 20) . The Forearm vascular responses to A VP. A brachial artery was cannulated with a 20-gauge intravascular over-the-needle Teflon catheter (Quick-cath; Travenol-Genentech Laboratories, Cambridge, MA) for drug infusion and a vein in the antecubital region of the same arm was cannulated to obtain blood samples for the measurements of plasma levels of AVP, cAMP, cGMP, and ionized calcium. After the placement of cannulae and a strain gauge plethysmograph, at least 15 min were allowed for the subjects to become accustomed to the study conditions before beginning the experiments. The arterial line was kept open by infusion of heparinized saline before drug infusion.
In six subjects, the dose-dependent effects of intraarterial AVP on forearm circulation were examined. AVP at rates of 0.05, 0.1, 0.2, 0.5, and 1.0 ng/kg per min were infused intraarterially for 2 min at each dose. Forearm blood flow was measured continuously in the ipsilateral arm during drug infusion. The volumes of infusion were 0.1, 0.2, and 0.4 ml/min for infusion rates of 0.05, 0.1, and 0.2 ng/kg per min, respectively, and 0.1 and 0.2 ml/min for infusion rates of 0.5 and 1.0 ng/kg per min, respectively.
In seven subjects, we attempted to explore the mechanisms whereby intraarterial AVP at higher doses produced forearm vasodilatation in healthy men. In these subjects, AVP at rates of 1.0 and 2.0 ng/kg per min were infused intraarterially. The volumes of infusion were 0.2 and 0.4 ml/min.
First, to exclude the possibility that the vasodilator effects of intraarterial AVP at higher doses might be mediated by the systemic neural effects (7, 8) , we measured forearm blood flow simultaneously in the contralateral and ipsilateral arms during intraarterial infusions ofAVP (n = 5).
Second, previous studies in humans and animals have suggested that AVP stimulates endogenous prostaglandin synthesis in blood vessels as well as in kidney (12, (21) (22) (23) (24) (25) . To examine the possibility that this mechanism might have contributed to vasodilatation, we studied forearm vascular responses to intraarterial AVP before and after the treatment with oral indomethacin at a dose of 75 mg/d for 3 d in the same subjects (n = 5).
Third, we examined the effect of increased plasma ionized calcium on forearm vascular responses to intraarterial AVP (n = 6). This study was done because a recent study in humans suggested that vasodilatation mediated by cGMP may be markedly attenuated by increased plasma-ionized calcium (26) . After the study with intraarterial infusion of AVP alone was completed, we began saline infusion and waited for at least 10 min, by which time forearm blood flow returned to the baseline value. Then, we started intraarterial infusion of isoosmolar calcium chloride at a dose of0.09 meq/min in a volume of0.2 ml/min. Calcium chloride was infused for 10 min and then we began simultaneous intraarterial infusions of calcium chloride and AVP at two doses. The volumes of infusion during simultaneous infusions of the two drugs were 0.4 and 0.6 ml/min. We confirmed that the increase in the volume of infusion by itself did not alter forearm blood flow.
Forearm vascular responses to sodium nitroprusside or isoproterenol. We also examined the effect of increased plasma-ionized calcium on forearm vasodilatation caused by intraarterial sodium nitroprusside or isoproterenol. The experiments were done in the same way as the study with AVP. First, forearm blood flow was measured during intraarterial infusion of sodium nitroprusside at doses of 1.7, 3.3, and 6.7 ng/kg per min (n = 3) or isoproterenol at doses of 0.08, 0.17, and 0.33 ng/kg per min (n = 4). Then, the measurements of forearm blood flow were repeated during simultaneous infusions of calcium chloride at a dose of 0.09 meq/min and sodium nitroprusside at three doses (n = 3) or isoproterenol at three doses (n = 4). The volumes of intraarterial infusion of sodium nitroprusside or isoproterenol were 0.1, 0.2, and 0.4 ml/min, and the volume of calcium chloride infusion was 0.2 ml/min. Preparation of A VP, sodium nitroprusside, and isoproterenol. 20 pressor units/ml synthetic AVP (Pitressin; Parke-Davis, Inc., Morris Plains, NJ) was diluted in physiological saline to a concentration of 30 or 300 ng/ml. Sodium nitroprusside (Wakou Junyaku Kougyou, Osaka, Japan), was dissolved in physiological saline at a concentration of 1,000 ng/ml. Special care was taken not to expose nitroprusside to light. Isoproterenol (Proterenol-L; Nikken Kagaku, Tokyo, Japan), 0.2 mg/ml, was diluted in physiological saline to a concentration of 50 ng/ml. Plasma levels of A VP, cAMP, cGMP, and ionized calcium. The plasma AVP levels in the venous effluents were determined during intraarterial infusion of saline and AVP at each dose. The venous plasma cAMP and cGMP levels were determined during infusion of saline and the maximal dose of AVP (2.0 ng/kg per min), sodium nitroprusside (6.7 ng/kg per min) or isoproterenol (0.33 ng/kg per min). Venous blood for the measurements of AVP, cAMP and cGMP were sampled into the tube containing EDTA-2K (1 mg/ml). Plasma AVP was measured in duplicate by RIA using RIA kits obtained from Mitsubishi Petrochemical Co. Ltd. (Tokyo, Japan), after Sep-Pak C 18 extraction of plasma as previously described (27, 28). Plasma cAMP and cyclic GMP were measured in duplicate by RIA using RIA kits obtained from Yamasa Shoyu Co. (Tokyo, Japan) after succinylation as previously described (29) . All measurements by RIA were performed in the laboratory of Bio-Medical Laboratories Co. (Tokyo, Japan). We also determined venous plasma ionized calcium by an autoanalyzer (Nova-2; Nova Biomedical Corp., Waltham, MA) during intraarterial infusion of saline and calcium chloride.
Statistical analysis. Statistical analysis of forearm vascular responses to intraarterial AVP, sodium nitroprusside or isoproterenol was performed with the use of a one-way analysis of variance (ANOVA). The Newman-Keuls multiple comparisons test was used to determine the level of statistical significance comparing the value at control with that at each dose ofthe drugs (30) . Two-way ANOVA was used to compare forearm vascular responses to AVP before indomethacin with those after indomethacin, and to compare responses to the drug alone with those to simultaneous infusion of the drug and calcium chloride. Paired t test was used to compare plasma concentrations of AVP, cAMP, cGMP and ionized calcium between saline and drug infusion.
All values are expressed as means±SE and P -0.05 was considered to be statistically significant.
Results
Responses to A VP (Table I and Table II) . Intraarterial infusions ofAVP at graded doses into a brachial artery did not alter mean blood pressure or heart rate. Forearm vascular responses to intraarterial AVP were biphasic. AVP at a dose of 0.05 ng/kg per min decreased forearm blood flow (P < 0.05) and AVP at doses of 0.05 and 0.1 ng/kg per min increased forearm vascular resistance (P < 0.01 and P < 0.05, respectively), whereas AVP at a dose of 0.2 ng/kg per min and higher increased forearm blood flow and decreased forearm vascular resistance (P < 0.05 for 0.2 ng/kg per min and P < 0.01 for higher doses). Representative plethysmographic recordings of forearm blood flows during intraarterial infusions of AVP at graded doses are shown in Fig. 1 . Percent changes in forearm vascular resistance induced by intraarterial AVP at graded doses are shown in Fig. 2 .
The relationship between plasma AVP levels and percent changes in forearm vascular resistance in each subject is shown in Fig. 3 . The venous plasma AVP levels increased in a dosedependent fashion (P < 0.01). The venous plasma AVP level that caused the maximal forearm vasoconstriction in an individual subject was 76.3±8.8 pg/ml. Forearm vascular resistance returned toward the control value or decreased as the venous plasma AVP levels were between 100 and 400 pg/ml, and forearm vasodilatation was induced in all subjects when 428 Suzuki, Takeshita, Imaizumi, Hirooka, Yoshida, Ando, and Nakamura the venous plasma AVP levels were > 400 pg/ml. The lowest venous plasma level associated with forearm vasodilatation in an individual subject was 369±43 pg/ml. Forearm blood flow and forearm vascular resistance in the contralateral arm did not change during intraarterial infusions of AVP at doses of 1.0 and 2.0 ng/kg per min, which caused forearm vasodilatation in the ipsilateral arm.
The treatment with indomethacin for 3 d did not significantly alter baseline mean blood pressure, heart rate, forearm blood flow, or forearm vascular resistance. Intraarterial infusions of AVP at doses of 1.0 and 2.0 ng/kg per min after the treatment with indomethacin increased forearm blood flow (P < 0.01) and decreased forearm vascular resistance (P < 0.01) in a dose-dependent fashion. The magnitudes of vasodilating responses to AVP did not differ before and after the treatment with indomethacin (Fig. 4) .
Intraarterial infusion of calcium chloride did not alter baseline mean blood pressure, heart rate, forearm blood flow, or forearm vascular resistance. However, simultaneous intraarterial infusion of calcium chloride totally inhibited vasodilating responses to AVP at doses of 1.0 and 2.0 ng/kg per min (Fig. 4) . Plasma ionized calcium of the venous effluent increased from 1.14±0.06 mM during saline infusion to 1.45±0.04 mM during infusion ofcalcium chloride (P < 0.01). Plasma levels of cGMP and cAMP did not change during intraarterial infusion of AVP at the dose of 2.0 ng/kg per min (cGMP 4.7±0.6 pmol/ml; cAMP 17.6±0.6 pmol/ml) as compared to those during saline infusion (cGMP 4.6±0.6 pmol/ ml; cAMP 15.9±1.0 pmol/ml, NS for both).
Responses to sodium nitroprusside or isoproterenol (Table   III and Table IV ). Intraarterial infusions of sodium nitroprusside or isoproterenol at graded doses did not alter mean blood pressure or heart rate. Intraarterial infusion of sodium nitroprusside or isoproterenol increased forearm blood flow (P < 0.05 for sodium nitroprusside and P < 0.01 for isoproterenol) and decreased forearm vascular resistance (P < 0.01 for both) in a dose-dependent fashion. The magnitudes of vasodilating responses to these two drugs were comparable. Intraarterial infusion of calcium chloride did not significantly alter baseline blood pressure, heart rate, forearm blood flow, or (Fig. 5) .
The plasma cGMP level in the venous effluent during infusion ofsodium nitroprusside at the dose of6.7 ng/kg per min (4.4±0.8 pmol/ml) did not differ from that during infusion of saline (4.5±0.6 pmol/ml). The plasma cAMP level in the venous effluent during infusion of isoproterenol at the dose of 0.33 ng/kg per min (16.5±1.9 pmol/ml) did not differ from that during infusion of saline (19.7±2.5 pmol/ml). Thus, sodium nitroprusside and isoproterenol failed to significantly increase plasma cyclic nucleotide levels although mediating vasodilation.
Discussion
The findings of this study allow three conclusions. First, AVP infused intraarterially at a dose of 0.2 ng/kg per min or higher exerts a direct vasodilator effect on forearm vessels in humans. In contrast, intraarterial AVP at lower doses causes forearm vasoconstriction. Second, the direct vasodilator effect of AVP at higher doses is not mediated by prostaglandins. Third, the vasodilator effect of AVP can be inhibited by an increase in plasma-ionized calcium. Forearm vasodilatation resulting from the direct effect of AVP on forearm vessels was an unanticipated finding in view of its known vasoconstrictor effect. Thus, in the Discussion, we will first consider how these observations relate to previous works in humans and, second, we will speculate on the mechanisms involved in the direct vasodilator effect of AVP.
A VP-induced vasodilatation in humans. Although AVP is a potent vasoconstrictor agent (1), AVP-induced vasodilatation has been observed in humans (4, 7, 8, 18) and in animals (12, 13) . In humans, several groups of investigators have demonstrated that intravenous infusion of AVP may cause forearm vasodilatation after > 10 min of intravenous infusion of AVP at a high dose (4 ng/kg per min or higher) (4, 7, 8) , which raised the plasma AVP level to 300 pg/ml (7, 8) . In contrast, it has been shown that a modest increase in the plasma AVP level to < 50 pg/ml caused by intravenous infusion of AVP at a low dose did not alter forearm vascular resistance (7) or produced vasoconstriction in muscle and skin (31, 32 (7, 8) .
This suggestion was based on findings that intravenous AVP at a high dose augmented reflex forearm vasodilatation in response to the acute rise in central venous pressure (7) and inhibited muscle sympathetic nerve activity recorded from the peroneal nerve (8) . This suggestion is supported by findings in animal studies that have shown that AVP augments reflex inhibition of sympathetic nerve activity mediated by arterial 100- and cardiopulmonary baroreceptors (9, (33) (34) (35) (36) (37) . However, it sodilatation caused by intraarterial AVP was the result of the appears that this mechanism does not totally account for foredirect effect of AVP because forearm blood flow measured arm vasodilatation observed in humans during intravenous simultaneously in the contralateral arm did not change (Tainfusion of AVP at higher doses. Kitchin has shown that ble II).
blocking ofthe deep nerves in the forearm by xylocaine did not The venous plasma AVP level associated with the maximal prevent forearm vasodilatation caused by intravenous AVP forearm vasoconstriction in an individual subject was (4). The effectiveness of nerve block was confirmed by the 76.3±8.8 pg/ml (Fig. 3) . Forearm vasodilatation was induced absence of sweating and the loss of voluntary movements (4).
at the venous plasma level of 369±43 pg/ml or higher (Fig. 3) . Forearm vascular responses to intraarterial infusion of In most subjects, forearm vascular resistance returned toward AVP also have been examined previously in humans (4, 18) . the baseline level as the venous plasma AVP level increased to Kitchin has shown that intraarterial AVP at a low dose (4.3 > 100 pg/ml (Fig. 3) , which suggests that the direct vasodilang/min) caused forearm vasoconstriction (4) . In contrast, a tory effect was activated at this plasma AVP level. In one preliminary report by Hirsch et al. has indicated that intraartesubject, forearm vasodilatation occurred at the venous plasma rial AVP at a very high dose (10 ng/kg per min) induced fore-AVP level of 160 pg/ml (Fig. 3) . These results raise the possiarm vasodilatation (18) . The results of this study provide exbility that forearm vasodilatation observed during intravenous planation for the difference between the two previous studies.
infusion ofAVP at a high dose in previous studies (7, 8) may in We found that intraarterial AVP caused forearm vasoconstricpart have resulted from the direct vasodilator effect of AVP. It tion when infused at doses of 0.05 and 0.1 ng/kg per min but has been suggested that the plasma AVP level may increase to produced forearm vasodilatation when infused at a dose of0.2 the level of 100-500 pg/ml with severe circulatory stress (38) . ng/kg per min or higher (Table I, Figs. 1 and 2) . At higher Thus, it appears that AVP at the pathophysiological plasma doses, intraarterial AVP caused forearm vasodilatation in a levels exerts the direct vasodilatory effect in humans. It is, dose-dependent fashion (Table I, Figs. 1 and 2 ). Forearm vahowever, important to note that AVP at the physiological plasma levels (< 100 pg/ml) caused forearm vasoconstriction (Fig. 3) .
Speculation on the mechanisms involved in the direct vasodilator effect ofA VP. Previous studies in humans and animals have suggested that AVP may stimulate several vasodilatory mechanisms, which include (a) facilitated reflex inhibition of sympathetic nerve activity (3, 5, (7) (8) (9) (10) (11) 39) ; (b) the increased synthesis of vasodilatory prostaglandins (12, 13) ; (c) release of the endothelium-derived relaxant factor (EDRF) (14) and (d) stimulation of the vascular V2 receptors (15) (16) (17) 40) . We considered whether any of these vasodilatory mechanisms might be responsible for forearm vasodilatation caused by intraarterial AVP in humans. However, as discussed previously, it is unlikely that sympathetic withdrawal was the cause of forearm vasodilation in our subjects. Forearm vasodilation was the result of the direct vasodilatory effect but not of the systemic effect. Therefore, we now consider the possibility that any of other three mechanisms might be involved in direct vasodilatation caused by AVP.
It has been shown that AVP stimulates the synthesis of prostaglandins in kidney (12, (21) (22) (23) (24) and vascular smooth muscles (25) . Oliver et al. and Seino et al. have shown that intrarenal infusion of AVP caused renal vasodilatation during or immediately after cessation of infusion and that such vasodilatation was effectively blocked by indomethacin (12, 13) . Similarly, Glanzer et al. have shown in humans that intravenous AVP increased systemic vascular resistance only after the treatment of indomethacin (6) . These observations have suggested that AVP stimulates prostaglandin-mediated vasodilatory mechanisms. However, in this study, the vasodilating responses to intraarterial AVP were not altered by indomethacin at a dose of 75 mg/d for 3 d (Fig. 4, Table II ). This dose of indomethacin has been shown to markedly potentiate the pressor response to intravenous angiotensin II in normal man (41) and to abolish the depressor effect of captopril in low renin hypertensive subjects (42) . It also has been shown that this dose of indomethacin markedly suppressed the urinary excretion of prostaglandin E metabolites by 7 1% and inhibited platelet aggregation in man (43) . These results suggest that indomethacin at a dose of 75 mg/d for 3 d inhibits synthesis of prostaglandins in various tissues in humans including vessels. Since indomethacin at this dose did not alter the responses evoked with intraarterial AVP, it is unlikely that AVP-induced forearm vasodilatation in our subjects was mediated by increased synthesis of prostaglandins.
Katusic et al. have reported that AVP caused endothelium-dependent vasorelaxation in the canine basilar and coronary artery in vitro ( 14) . Thus, we need to consider the possibility that AVP-induced forearm vasodilatation might have been mediated by EDRF. However, it is not possible to examine in humans in a decisive way whether or not EDRF is involved in vasodilatation. We, therefore, asked whether AVP-induced vasodilatation was mediated by cGMP. It is known that endothelium-dependent vasorelaxation is mediated by cGMP (44) (45) (46) (47) (48) . We examined the effect of intraarterial infusion of calcium chloride on AVP-induced forearm vasodilatation, since Fujita et al. have previously shown in humans that intraarterial calcium chloride at a rate of 0.09 meq/min markedly attenuated cGMP-mediated vasodilatation induced by a-human atrial natriuretic peptide (26) . The results indicate that intraarterial calcium chloride inhibited AVP-induced forearm vasodilatation (Table II, Fig. 4 ). We also examined the effect of intraarterial calcium chloride on forearm vascular responses to intraarterial sodium nitroprusside and isoproterenol. Calcium chloride significantly attenuated nitroprusside-induced forearm vasodilatation but did not alter isoproterenol-induced vasodilatation (Tables III and  IV, Fig. 5 ). Although the mechanisms are not clear, these results are compatible with the suggestion by Fujita et al. (26) that intraarterial calcium chloride attenuates cGMP-mediated vasodilatation but not cAMP-mediated vasodilatation. Based on these results, we speculate that AVP-induced forearm vasodilatation may be mediated by cGMP. We obviously do not know the mechanisms by which AVP may activate cGMPmediated vasodilatation. However, it might be possible that EDRF is involved, as shown in a previous study in vitro (14) .
In this regard, we also measured the venous plasma level of cGMP and cAMP during intraarterial infusion of AVP. However in our subjects, venous plasma cGMP or cAMP did not change during intraarterial infusion of AVP. Venous plasma cGMP or cAMP also did not change during intraarterial infusion of sodium nitroprusside or isoproterenol, respectively. Thus, local elevations of cyclic nucleotides may not be reflected by an increase in plasma cyclic nucleotide levels. Therefore, the inability to determine an increase in plasma cyclic nucleotide levels with AVP infusion did not rule out a role of cyclic nucleotides as second messengers of AVP-mediated vasodilation. It should be noted that failure to detect the increase in cGMP during infusion of sodium nitroprusside was not due to the inadequate sensitivity of the assay system. In another study, we have observed using the same assay system as used in this study that intraarterial infusion of atrial natriuretic peptide increased venous plasma cGMP (unpublished observation). The latter finding is consistent with the results of other investigators (26) . Interestingly, we have noted that intraarterial infusion of nitroglycerin did not increase venous plasma cGMP (unpublished observation). It has been suggested that atrial natriuretic peptide stimulates particulate guanylate cyclase, whereas sodium nitroprusside and nitroglycerin activate soluble guanylate cyclase (49) . Thus, it ap-pears that plasma cGMP may increase when the formation of cGMP is catalyzed by particulate guanylate cyclase but not by soluble guanylate cyclase.
The other mechanism that we need to consider is vascular V2 receptor-mediated vasodilatation. Recent studies have shown that intravenous AVP decreased total peripheral vascular resistance after selective blockade of vasopressinergic (VI) receptors (15) (16) (17) 40) and that this vasodilatation was not blocked by propranolol, atropine, or indomethacin (16, 17, 40) . It also has been shown that intravenous infusion of an analogue with selective antidiuretic activity decreased total peripheral vascular resistance (40) . These results suggest that AVP may cause vasodilatation by stimulating the V2 receptors. However, we consider that this mechanism was unlikely to be involved in AVP-induced forearm vasodilatation in our subjects, because AVP apparently induces V2 receptor-mediated vasodilatation only after blockade of the V1 receptors (15) (16) (17) 40) .
In summary, intraarterial AVP caused forearm vasoconstriction at the lower and physiological plasma levels, whereas it caused forearm vasodilatation at the higher and pathophysiological plasma levels. The vasodilator effect of AVP was unlikely to be mediated by increased synthesis of prostaglandins or reflex sympathetic withdrawal. The vasodilator effect of AVP was inhibited by an increase in plasma-ionized calcium. Because increased plasma-ionized calcium attenuated nitroprusside-induced vasodilation, but not isoproterenol-induced vasodilation, it is possible that the direct vasodilatory effect of AVP may be mediated by cGMP-related mechanisms.
